Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. The emerging biotech BetterLife Pharma Inc. (OTCQB:BETRF) has filed an international PCT along with a U.S. patent application for the composition and use within the treatment of LSD derivatives for mental health conditions such as depression, PTSD, anxiety, cluster headaches and pain.
在努力發現和推進治療迷幻藥的同時，生物製藥公司是 繼續保護他們的發現。新興的生物技術BetterLife Pharma Inc.(場外交易代碼：BETRF)已經提交了一份國際PCT與美國專利申請用於治療精神健康疾病，如抑鬱症、創傷後應激障礙、焦慮、叢集性頭痛和疼痛的LSD衍生物的組成和使用。
One of BetterLife's main compounds under development, BETR-001, will be covered by these patent filings. The proprietary drug is a new composition of 2-bromo-LSD and a second-gen LSD derivative molecule that does not cause hallucinations and therefore is not subject to global controlled substance regulations.
BetterLife正在開發的主要化合物之一，BETR-001，將被這些專利申請所涵蓋。該專利藥物是2-溴-LSD和第二代LSD衍生分子的新組合物，不會導致幻覺，因此不受全球受控物質監管。
BETR-001's synthesis is done through non-controlled substance synthetic routes, which also makes it not subject to controlled substance regulatory restrictions and therefore plausible for self-administration.
完成了Betr-001的合成通過非管制物質合成路線這也使其不受受控物質監管限制，因此對自我管理是合理的。
The company is at advanced stages of GMP-manufacturing and completion of preclinical IND-enabling studies for BETR-001, expecting to file the IND and begin Phase 1 clinical studies in the first half of 2023.
該公司目前在 GMP生產的高級階段和臨牀前IND使能研究的完成對於BETR-001，預計將在2023年上半年提交IND並開始第一階段臨牀研究。
CEO Dr. Ahmad Doroudian explained that the inventions covered by the patent filings are comprehensive and "involve a significant body of data including composition of matter, preclinical in-vitro and in-vivo characterization of BETR-001," which the company expects to soon submit for publication in a peer-reviewed journal.
首席執行官艾哈邁德·多魯迪安博士解釋説，專利申請所涵蓋的發明是全面並“涉及大量數據，包括BETR-001的物質組成、臨牀前體外和體內表徵”，該公司預計很快就會提交給同行評議的期刊發表。
Considering the data generated to date, the company believes its proprietary drug "holds great promise in becoming a major treatment for a range of mental health and neurological conditions, including depression, anxiety, pain and related disorders."
考慮到迄今為止生成的數據該公司認為，其專利藥物“很有希望成為治療一系列心理健康和神經疾病的主要藥物，包括抑鬱、焦慮、疼痛和相關障礙。”
Betterlife's other main drug development, BETR-002, is currently in preclinical and IND-enabling studies. This proprietary compound is based on honokiol, the active anxiolytic ingredient of magnolia bark, and its pending method of use and formulations patent covers the treatment of anxiety-related disorders, including benzodiazepine dependence.
Betterlife的其他主要藥物開發, BETR-002，目前正在進行臨牀前和支持IND的研究。這種專利化合物是厚朴抗焦慮活性成分和厚朴酚，其正在申請的使用方法和配方專利涵蓋了治療焦慮症相關疾病，包括苯二氮卓類依賴。
Photo courtesy of Olia Danilevich on Pexels.
照片由Olia Danilevich在Pexels上提供。
譯文內容由第三人軟體翻譯。